New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.

The data shows remestemcel-L reduced mortality through day 60 by 46 percent in the pre-specified group (below age 65 years), but not in patients 65 years or older.

Additionally, remestemcel-L reduced mortality by 75 percent and increased days alive off mechanical ventilation in patients under age 65 when combined with dexamethasone, in comparison with controls on dexamethasone.

The trial enrolled 222 mechanically ventilated COVID-19 patients with moderate/severe ARDS, of whom 217 were randomised 1:1 to receive either standard of care (SOC) alone or SOC plus two intravenous infusions of remestemcel-L three to five days apart at a dose of two million cells/kg.

Read More